Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Endocrine 1 CNS 1

Conditions

Pheochromocytoma 1 Paraganglioma 1 Osteoporosis 1 Obesity 1 Insulinoma 1 Hypertension 1 Hypercholesterolemia 1 Hyperaldosteronism 1 Growth Hormone-Secreting Pituitary Adenoma 1 Diabetes Mellitus 1 Cushing Syndrome 1 Cardiomyopathies 1 Carcinoma, Neuroendocrine 1 Adrenocortical Carcinoma 1 Adrenal incidentaloma 1 Adrenal Gland Neoplasms 1 Acromegaly 1

Interventions

3-Iodobenzylguanidine 8 lutetium Lu 177 dotatate 6 gallium Ga 68 dotatate 5 Temozolomide 4 Specimen Handling 4 Magnetic Resonance Spectroscopy 4 anlotinib 3 Everolimus 3 olaparib 2 cabozantinib 2 belzutifan 2 Sunitinib 2 Phenoxybenzamine 2 Nivolumab 2 Fluorodeoxyglucose F18 2 Biopsy 2 Axitinib 2 3-fluorobenzylguanidine 2 177Lu-octreotide, DOTA(0)-Tyr(3)- 2 vandetanib 1 talazoparib 1 spartalizumab 1 pembrolizumab 1 pazopanib 1 lanreotide 1 guadecitabine 1 fluorodopa F 18 1 fludarabine phosphate 1 copper dotatate CU-64 1 cixutumumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Paraganglioma × Observation × Endocrine × Clear all

NCT05082311 2022-02-10

PheoCard

Sanjay Gandhi Postgraduate Institute of Medical Sciences

Cardiomyopathies, Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡